Bristol Myers Squibb CO Form 4 insider transactions

Director Michael R. McMullen's family trust closed a covered call option position on Bristol-Myers Squibb shares.

Director Michael R. McMullen acquired 2,986.941 deferred share units of Bristol-Myers Squibb on July 1, 2024, convertible to common stock upon ceasing to be a director or at a specified future date.

Director Phyllis Yale reported the acquisition of deferred share units in Bristol-Myers Squibb on June 30, 2024.

Director Theodore R. Samuels II reports acquisition of deferred share units in Bristol-Myers Squibb Co.

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Director Deepak Bhatt acquired deferred share units of Bristol-Myers Squibb, convertible to common stock upon cessation of directorship or at a specified future date.

Director Peter J. Arduini reports acquisition of deferred share units in Bristol-Myers Squibb Co. on June 30, 2024.

EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports changes in beneficial ownership of company stock and market share units.

EVP Karin Shanahan reports transactions involving Bristol-Myers Squibb common stock and restricted stock units.

Director Phyllis Yale reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Director Gerald L. Storch reports acquiring deferred share units of Bristol-Myers Squibb, convertible to common stock upon departure from the board or at a specified future date.

Director Theodore R. Samuels II reports acquisition of deferred share units in Bristol-Myers Squibb Co.

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Director Deepak Bhatt acquired deferred share units in Bristol-Myers Squibb, convertible to common stock upon leaving the board or at a specified future date.

Director Peter J. Arduini reports acquisition of deferred share units convertible to common stock in a recent transaction.

EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports transactions involving common stock and market share/performance units, including vesting, adjustments, and tax withholdings.

EVP and General Counsel of Bristol-Myers Squibb, Sandra Leung, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.

Robert M. Plenge, EVP and Chief Research Officer at Bristol-Myers Squibb, reports transactions involving common stock and market share units.

EVP and Chief Human Resources Officer Amanda Poole Ahn reports transactions involving Bristol-Myers Squibb common stock and derivative securities, including vesting of market share units and performance shares.

Samit Hirawat, EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, reports transactions involving common stock and market share/performance units, including vesting, adjustments, and shares withheld for taxes.

Phil M. Holzer, SVP and Controller of Bristol-Myers Squibb, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.

Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb, reports transactions involving common stock and market share/performance units, including vesting, adjustments, and tax withholdings.

EVP Cari Gallman reports transactions involving Bristol-Myers Squibb common stock and market share units, including vesting, adjustments, and tax withholdings, as per Form 4 filing.

CEO Christopher Boerner reports transactions involving Bristol-Myers Squibb common stock and market share/performance units, including vesting, adjustments, and tax withholdings.

EVP Karin Shanahan reports transactions involving Bristol-Myers Squibb stock and derivative securities, including the cancellation and acquisition of market share units and performance shares.

EVP, Chief Digital & Tech Officer of Bristol-Myers Squibb, Gregory Scott Meyers, reports acquisition and disposal of market share units and performance shares.

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports acquisition of market share units and performance shares.

David Elkins, EVP and CFO of Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and performance shares.

Giovanni Caforio, Executive Chair of Bristol-Myers Squibb, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the acquisition of 9,858 restricted stock units (RSUs) that will vest over three years.